ClinicalTrials.gg
Not yet recruitingNCT07134218Updated Aug 21, 2025

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

A Phase 2/3 interventional study of serplulimab、bevacizumab and neoadjuvant chemoradiation therapy in Rectal Cancer, sponsored by Changhai Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Changhai Hospital · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
118th of 373
180 · median 100
Started
2025
with 68 others
Phase 2/3
15 of 463
9 open now
Primary completion
2027-10
later than 178 of 266 live
Registered
381st of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 118th largest by planned enrollment of the 373 interventional ones that give a count, is one of 69 that started in 2025, is one of 15 in phase 2/3, reaches primary completion later than 178 of the 266 other live ones, and was the 381st registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized phase II trial designed to evaluate the efficacy and safety of short-course neoadjuvant chemoradiotherapy combined with the PD-1 monoclonal antibody serplulimab and the anti-angiogenic agent bevacizumab in patients with previously untreated pMMR/MSS middle and low locally advanced rectal cancer. The study plans to enroll a total of 200 participants (100 in the experimental arm and 100 in the control arm).

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written to voluntarily participate in the study;
  • Aged 18 to 75 years, inclusive, regardless of sex;
  • confirmed rectal adenocarcinoma with immunohistochemistry results showing proficient mismatch repair (pMMR) or molecular testing results indicating microsatellite stability (MSS);
  • Clinical baseline staging assessed by MRI as T3-4N0M0/TanyN+M, with negative mesorectal fascia (MRF);
  • Tumor lower margin ≤7 cm from the anal verge;
  • Surgically resectable;
  • Capable of swallowing tablets normally;
  • Performance Status (ECOG PS) 0-1;
  • No prior anti-tumor treatment for rectal cancer, including radiotherapy, chemotherapy, or surgery;
  • Planned to undergo surgical treatment after completion of therapy;
  • No to surgery;
  • Normal function of major organs.

Exclusion criteria

Exclusion Criteria:

  • History of allergy to any component of bevacizumab, serplulimab, 5-FU, or oxaliplatin.
  • Prior or ongoing treatment with any of the following:

    1. Any tumor-targeted surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
    2. drugs or systemic therapy for immunosuppressive purposes within 2 weeks before the first administration of the study drug (dose > 10 mg/day prednisone or equivalent). Inhaled or topical corticosteroids and adrenal corticosteroid replacement therapy (dose > 10 mg/day prednisone or equivalent) are permitted in the absence of active disease.
    3. within 4 weeks before the first administration of the study drug.
    4. Major surgery or severe trauma within 4 weeks before the first administration of the study drug.
  • Presence of any active autoimmune disease or history of autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (participants on hormone replacement therapy may be considered for inclusion). Participants with psoriasis or childhood asthma/allergy that has fully resolved and requires no intervention in adulthood may be considered for inclusion, but those requiring bronchodilator therapy are not eligible.
  • History of immunodeficiency, including positivity, or other acquired or congenital immunodeficiency diseases, or history of organ transplant or bone marrow transplant.
  • Uncontrolled cardiac symptoms or diseases, including but not limited to: (1) class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within the past year, (4) supraventricular or ventricular arrhythmias that are not controlled or remain poorly controlled after clinical intervention.
  • Severe infection ( > grade 2) within 4 weeks before the first administration of the study drug, such as severe pneumonia, bacteremia, or infection with complications requiring hospitalization. Baseline chest imaging showing active pulmonary inflammation, or presence of signs and symptoms of infection or need for oral or intravenous antibiotic therapy within 14 days before the first administration of the study drug (excluding prophylactic antibiotic use). History of active pulmonary tuberculosis infection identified through medical history or CT scan, or history of active pulmonary tuberculosis infection within the past year, or history of active pulmonary tuberculosis infection more than 1 year ago that was not properly treated.
  • Active (HBV DNA ≥ 2000 IU/mL or 10⁴ copies/mL), (positive HCV antibody and HCV RNA above the lower limit of detection of the assay).
  • Diagnosis of other within 5 years before the first administration of the study drug, unless the malignancy has a low risk of or death (5-year survival rate > 90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ, which may be considered for inclusion.
  • Pregnant or breastfeeding women.
  • Presence of other factors that, in the investigator's judgment, may lead to forced discontinuation of the study, such as other severe diseases (including psychiatric conditions) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the participant's safety or compliance.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    neoadjuvant chemoradiation therapy + serplulimab + bevacizumab

    Drug: serplulimab、bevacizumab

  • Other
    neoadjuvant chemoradiation therapy

    Drug: serplulimab、bevacizumab · Other: neoadjuvant chemoradiation therapy

Interventions

  • Drugserplulimab、bevacizumab

    short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 2 cycles of FOLFOX + serplulimab + bevacizumab → 2 cycles of FOLFOX + serplulimab.

  • Otherneoadjuvant chemoradiation therapy

    short-course radiotherapy 25 Gy in 5 fractions → 2-week break → 4 cycles of FOLFOX alone.

06

What researchers measure

Primary outcomes

  1. The rate of cCR

    Rate of patients who achieve clinical complete response

    Time frame: 2 years

Secondary outcomes

  1. Major Pathological Response

    Rate of major pathological response assessed by postoperative pathology

    Time frame: 2 years

  2. Objective Response Rate

    Objective response rate assessed by RECIST 1.1 criteria

    Time frame: 2 years

  3. Disease-Free Survival (DFS)

    DFS was defined as the duration from the date of randomization to the date of the first recurrence (local, distant, or mixed) or death.

    Time frame: 2 years

  4. Overall Survival (OS)

    Time from randomization to death due to any cause

    Time frame: 2 years

  5. Organ Preservation Rate (OPR)

    Proportion of patients who achieve organ preservation by choosing a watch-and-wait strategy or local excision after attaining clinical or pathological complete response

    Time frame: 2 years

  6. Neoadjuvant Rectal Score (NAR)

    Neoadjuvant rectal score assessed by postoperative pathology

    Time frame: 2 years

  7. Quality of Life Score (QoL)

    Quality of life score during treatment and follow-up

    Time frame: 2 years

  8. Safety and Tolerability

    Incidence of adverse events (AEs), incidence of abnormal laboratory values, and dose adjustments during treatment and follow-up

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD would be available upon reasonable request.

Supporting information: Study protocol

Time frame: 2 years

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Oct 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartEst.
Oct 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134218
Lead sponsor
Changhai Hospital
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Oct 2025 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Aug 21, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion